Tenderwize
Zurück zur Suche

Open-house drug rebate agreements Mecklenburg-Vorpommern

AOK Nordost - Die Gesundheitskasse·Potsdam, Germany·Deadline Feb 21, 2027 · 180 days left·Open·Supplies
Originaltitel der Bekanntmachung

Germany – Pharmaceutical products – Open-House-Arzneimittelrabattverträge gemäß § 130a Abs. 8c SGB V für die KV-Region Mecklenburg-Vorpommern

62/100

Opportunity Score

Needs reviewMedium complexity
SuppliesOpen
Warum diese Bewertung?

Chance

62 / 100

Komplexität

58 / 100

Risikofaktoren

The notice text says contract conclusion is possible until 21.02.2026, but the publication date is 11.02.2026 and the n...

A document URL is provided, but no full procurement document text beyond the TED XML notice was analyzed.

Tiefe Portfolioanalyse

Tiefe Analyse der Unternehmenspassung

Verwendet:

  • Description
  • Industries & Services
  • Capabilities
  • Market & Experience
  • Certifications

Überblick

Moderate opportunity

Wichtige Fakten

  • Supplies contract
  • 3 lots
  • Duration until Apr 2027
  • Open-House pharmaceutical rebate agreements under § 130a(8c) SGB V for the Mecklenburg-Vorpommern region.
  • Supply of oncology-related parenteral preparations made from finished medicinal products for immediate physician use in pharmacies.
Vollständige Zusammenfassung anzeigen

This is an Open-House pharmaceutical rebate agreement notice for Mecklenburg-Vorpommern, covering three active substances: Bevacizumab, Rituximab, and Trastuzumab. The lead buyer is AOK Nordost, with several other health insurers listed as participating buyers. The model is non-exclusive, with no selection among bidders, and contracts are offered on identical, non-negotiable terms to all eligible pharmaceutical companies. Submission is allowed electronically and by signed paper originals; the notice states that documents are available via DTVP, but the extracted procurement documents were not fully analyzed beyond the TED XML notice text. The estimated contract value is not provided.

Risiken

The notice text says contract conclusion is possible until 21.02.2026, but the publication date is 11.02.2026 and the n...

A document URL is provided, but no full procurement document text beyond the TED XML notice was analyzed.

Analyse kann unvollständig sein

Nur ein Teil der Vergabeunterlagen wurde analysiert. Weitere Anforderungen, Zertifikate oder Einreichungsdokumente können in den übrigen Unterlagen enthalten sein.

Wichtige Anforderungen

Technical

  • The contract signatory must have authority shown in the commercial register extract; otherwise a power of attorney must be provided.

Eligibility

  • Only pharmaceutical companies are eligible as potential contract partners.

Administrative

  • Submit the signed contract, the completed file 'OHV_8c_Mecklenburg-Vorpommern_Festlegung_[Wirkstoffname]_PZN', and the signed reliability declaration.

Auftraggeber

Ort

Potsdam, DEU

Website

www.aok.de

Kennung

DE275390265

Tätigkeit

Health

Lose (3)

LOT-0001

Bevacizumab

Open-House rebate agreement for Bevacizumab (ATC L01FG01) for the Mecklenburg-Vorpommern region. The notice states this is not a competitive award procedure but a non-exclusive Open-House model for pharmaceutical companies supplying parenteral oncology preparations for immediate physician use in pharmacies. Contract terms are identical and non-negotiable. The lot-specific selection criteria in the structured data are an expression of interest, reliability declaration, and in the XML notice also current business liability insurance and a trade register extract not older than 2 years.

SuppliesEU fundedElectronic submission

Ort

Germany

Dauer

Apr 2026 - Apr 2027

Kategorie

Pharmaceutical products

Frist

Deadline Feb 21, 2027

LOT-0002

Rituximab

Open-House rebate agreement for Rituximab (ATC L01FA01) for the Mecklenburg-Vorpommern region. The notice states this is a non-exclusive Open-House model for pharmaceutical companies and not a selection-based procurement. Lot-specific eligibility in the structured data is a reliability declaration; the XML notice also mentions current business liability insurance and a trade register extract not older than 2 years.

SuppliesEU fundedElectronic submission

Ort

Germany

Dauer

Apr 2026 - Apr 2027

Kategorie

Pharmaceutical products

Frist

Deadline Feb 21, 2027

LOT-0003

Trastuzumab

Open-House rebate agreement for Trastuzumab (ATC L01FD01) for the Mecklenburg-Vorpommern region. The notice states this is a non-exclusive Open-House model for pharmaceutical companies and not a selection-based procurement. Lot-specific eligibility in the structured data is a sanctions declaration; the XML notice also mentions current business liability insurance and a trade register extract not older than 2 years.

SuppliesEU fundedElectronic submission

Ort

Germany

Dauer

Apr 2026 - Apr 2027

Kategorie

Pharmaceutical products

Frist

Deadline Feb 21, 2027

Vergabedetails

Veröffentlichungsdatum
11 Feb 2026
Sprachen
German

Referenzmetadaten

Rechtsgrundlage
32014L0024

Referenz-IDs

Ausschreibungs-ID
103191-2026

Dokumente (2)

Ähnliche Ausschreibungen